05.08.2015

SCQM Daten zum Thema Anämie bei Rheumatoider Arthritis wecken internationales Interesse

Ein im Mai 2015 erschienener Artikel von Prof. Dr. Daniel Aletaha „New insights into the measurement of disease activity in rheumatoid arthritis“ macht aufmerksam auf die in ARD 2014 veröffentlichte Studie von Prof. Dr. Burkhard Möller und Kollegen.

Die auf SCQM Daten basierende Studie von Prof. Dr. Burkhard Möller und Kollegen „Anemia may add information to standardized disease activity assessment to predict radiographic damage in Rheumatoid Arthritis – a prospective cohort study“,welche im April 2014 in den Annals of Rheumatic Diseases erschien, stößt auf internationales Interesse und wird in einer Jahreszusammenfassung von Prof. Dr. Daniel Aletaha zusammengefasst: 

Another study looked at the value of haemoglobin as a measure of disease activity. Anaemia is not part of the core set, but is a well known marker of chronic inflammation. The Swiss study by Möller et al. found on the basis of a large-scale, real live observational dataset that anaemia predicts worse outcome in RA. The authors found that anaemic patients progressed by on average 2.0% of the maximal score, while nonanaemic patients progressed 1.2%. This difference increased with the definition of more severe anaemia and was smaller when using a definition of mild anaemia. Importantly, the associations with structural outcomes in this study were independent of traditional disease activity measures (i.e. they were adjusted for DAS28 or Clinical Disease Activity Index, CDAI). Results were reproduced when only the subset of RA patients without use of nonselective nonsteroidal anti-inflammatory drugs were excluded, or if the subset of patients treated with antitumour necrosis factor alpha therapy were analysed. On the basis of the results of this study, it seems to be valuable to consider haemoglobin levels in the consideration of disease activity and risk assessment of patients with RA.

Prof. Möller’s Anämie Studie wurde anlässlich des Jahreskongresses der Schweizerische Gesellschaft für Rheumatologie in Interlaken 2014 mit dem mit CHF 60‘000.—dotierten Forschungspreis für „rheumatoide Arthritis“, gestiftet von der Fondation  „Jean & Linette Warnery“ ausgezeichnet.